
Opinion|Videos|December 8, 2023
Evaluating the Impact of Elacestrant Use in Clinical Practice for Patients With ER+/HER2-Metastasized Breast Cancer
Author(s)Joyce O'Shaughnessy, MD
Identifying the impact of elacestrant in clinical practice for patients with ER+/HER2- metastatic breast cancer.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Alpelisib/Fulvestrant Improves PFS in Post-CDK4/6 HR+/HER2- Breast Cancer
2
Gedatolisib Improves PFS in HR+/HER2-/PIK3CA-WT Advanced Breast Cancer
3
FDA Approves Niraparib/Abiraterone Combo for BRCA2-Mutated mCSPC
4
Nadunolimab Misses Efficacy Mark in TNBC, Despite Strong OS
5










































